Abstract-Blockade of angiotensin II (Ang II) function during 8 days of oral therapy with lisinopril (20 mg/kg) and losartan (10 mg/kg) normalized the arterial pressure (112Ϯ3/70Ϯ3 mm Hg) and raised the plasma concentrations of the vasodilator peptide angiotensin-(1-7) [Ang-(1-7)] of 21 male spontaneously hypertensive rats (SHR). Treated animals were then given a 15-minute infusion of either mouse immunoglobulin G 1 or a specific monoclonal Ang-(1-7) antibody while their blood pressure and heart rate were recorded continuously in the awake state. The concentrations of Ang II and Ang-(1-7) in arterial blood were determined by radioimmunoassay. Infusion of the Ang-(1-7) antibody caused significant elevations in mean arterial pressure that were sustained for the duration of the infusion and were accompanied by transient bradycardia. Although the hemodynamic effects produced by infusion of the Ang-(1-7) antibody had no effect on plasma levels of Ang II, they caused a twofold rise in the plasma concentrations of Ang-(1-7 Key Words: angiotensin-(1-7) Ⅲ angiotensin peptides Ⅲ receptors, angiotensin Ⅲ blood pressure Ⅲ losartan Ⅲ renin-angiotensin system P revious studies from this laboratory showed that the heptapeptide Ang-(1-7) is a biologically active component of the renin-angiotensin system that acts to oppose the pressor and proliferative actions of Ang II by stimulation of vasodilator prostaglandins, increased production of nitric oxide, or both.
P
revious studies from this laboratory showed that the heptapeptide Ang-(1-7) is a biologically active component of the renin-angiotensin system that acts to oppose the pressor and proliferative actions of Ang II by stimulation of vasodilator prostaglandins, increased production of nitric oxide, or both. 1 The vasodepressor actions of Ang-(1-7) are particularly distinct in conditions of high plasma renin activity, a finding that suggests that this heptapeptide may oppose the hypertensive actions of Ang II. 1 Characterization of the enzymatic pathways responsible for the synthesis and metabolism of Ang-(1-7) provides additional evidence for this proposal. Ang-(1-7) is generated from Ang I by tissue-specific endopeptidases 2, 3 and from Ang II by a postproline carboxypeptidase. 4 Ang-(1-7) is catabolized into smaller fragments [Ang-(2-7) and Ang-(3-7)] by aminopeptidases and into Ang-(1-5) by ACE. 5, 6 Characterization of the metabolic pathways leading to the formation and catabolism of the heptapeptide led to the demonstration that ACE inhibition is associated with significant increases in the circulating levels of Ang-(1-7). [7] [8] [9] [10] Because the hemodynamic and hormonal effects produced by Ang-(1-7) resemble those produced during chronic blockade of ACE, 11 we evaluated whether high circulating levels of Ang-(1-7) may contribute to the normalization of arterial pressure. To test this hypothesis, we measured the effect of endogenous neutralization of circulating Ang-(1-7) on the blood pressure of SHR treated with a combination of an ACE inhibitor and an Ang II subtype 1 receptor antagonist for 9 days before experimentation.
Methods
Studies were performed in 27 12-week-old male SHR (273Ϯ6 g, Charles River Laboratories Inc), housed individually in a room maintained at 22°C with a 12-hour light/dark cycle. Animals were fed rat chow (Purina Mills Inc) that provided a daily intake of 17 mmol of sodium and 28 mmol of potassium per 100 g of solid weight. Experiments were performed in accordance with the guidelines of the Animal Care and Use Committee of the Bowman Gray School of Medicine.
Twenty-one rats were medicated with a combination of lisinopril and losartan potassium, whereas 6 other rats were medicated with losartan only. All drugs were given per os for 9 days by dissolving the stock solution into the drinking tap water. The concentration of the drugs was adjusted daily by measuring the water intake during the preceding 24 hours. SHR received lisinopril at an average dose of 21Ϯ1 mg/kg per day, whereas the dose of losartan was 11Ϯ2 mg/d. Each drug was given at doses producing sustained therapeutic effects in previous experiments. 7, 8, 12 Systolic blood pressure was recorded by the tail-cuff method (Narco Bio-Systems) for 1 week before the initiation of the treatment to verify that the SHR were indeed hypertensive.
Animal Protocols
On day 8 of the treatment period, a plastic catheter (PE-50, Clay Adams, Becton Dickinson) was implanted under aseptic conditions into a carotid artery of rats given inhalation anesthesia (1% halothane, Ayerst Laboratories Inc, in 95% O 2 /5% room air). A second PE-50 catheter was implanted into a jugular vein. The free end of each catheter was tunneled cephalad and exteriorized at the nape of the neck. Direct measurements of arterial pressure and heart rate were obtained in awake, freely moving rats 24 hours later. On the day of the experiment, blood pressure was recorded continuously with a straingauge transducer (Uniflow Pressure Transducer, Baxter Healthcare Corp) connected to the arterial line. The electronic signal was directed to an analog-to-digital converter for beat-by-beat analysis of arterial pressure and heart rate as described in detail elsewhere. 13 Calibrated displays of systolic, diastolic, and mean arterial pressure and heart rate were imaged on a laser printer.
After an initial 30-minute stabilization period, arterial pressure and heart rate were recorded for 1 hour. Next, either an Ang-(1-7)-Ab (400 g/min) or IgG 1 (400 g/min) was infused intravenously at a rate of 50 L/min for 15 minutes. The dose of the Ang-(1-7)-Ab used here was shown in preliminary experiments to produce a maximal inhibition of the hemodynamic effects evoked by a bolus intravenous injection of 100 nmol of Ang-(1-7). 13 Ang II (0.1 mol/kg) was also injected intravenously before the infusion of the Ang-(1-7)-Ab or the control IgG 1 to ascertain the extent of AT 1 receptor blockade. Samples of arterial blood were collected before and after administration of IgG 1 or the Ang-(1-7)-Ab to assay plasma levels of Ang-(1-7) and Ang II. 
Ang-(1-7)-Abs
The (1-7), and the free ligand was separated by adding a suspension of activated charcoal/dextran. The binding data were analyzed and graphed using a Prism-plotting and statistical program (Graph Pad Inc). The method for iodination and purification of [
125 I]Ang-(1-7) to a specific activity of 2200 Ci/mmol has been described. 14 Protein concentration was determined with a Bradford protein assay kit using an IgG 1 standard (BioRad).
Angiotensin Assays
Plasma concentrations of Ang II and Ang-(1-7) were determined as described previously. 15, 16 Arterial blood was collected in a cocktail of protease inhibitors (25 mmol/L EDTA, 0.44 mmol/L o-phenanthroline, and 0.12 mmol/L pepstatin A). 17 Plasma was extracted using Sep-Pak columns activated with 5-mL sequential washes of a mixture of ethanol/water/4% acetic acid (83:13:4), methanol, ultrapure water, and 4% acetic acid. After the sample was applied to the column, it was washed with ultrapure water and acetone and eluted with 2:1 mL and 1:1.5 mL washes of a mixture of ethanol/water/4% acetic acid. The sample was reconstituted in assay buffer. Ang II was measured using the Nichols Institute radioimmunoassay, whereas Ang-(1-7) was detected using an antibody characterized by us in detail previously. 7, 15, 17 Recoveries of radiolabeled angiotensins added to the sample and followed through the extraction were 92%. Samples were corrected for recoveries as described by us previously. 17, 18 The minimum detectable levels of the assay were 4 pmol per tube for Ang II and 2.5 pmol per tube for Ang-(1-7). The intra-assay coefficient of variation averaged 12% for Ang II (29.6Ϯ3.6 pmol/L, nϭ24) and 8% for Ang-(1-7) (186Ϯ14 pmol/L, nϭ21).
Statistical Analysis
Data are expressed as meanϮSEM and analyzed by repeated measures ANOVA followed by Scheffé's test. A value of PϽ.05 was considered statistically significant.
Results

Characterization of the Ang-(1-7)-Ab
Fig 1 shows that the antibody produced by the G3-A10 clone was selective for Ang- (1) (2) (3) (4) (5) (6) (7) . Among the various peptides tested for displacement of [
125 I]Ang-(1-7), the native peptide showed the lowest IC 50 value (0.12 pmol). In comparison to Ang-(1-7), the N-terminal fragments Ang-(2-7) and Ang-(3-7) exhibited a cross-reactivity of 1.25% (IC 50 of 7.5 pmol) and 0.63% (IC 50 of 20.0 pmol), respectively. Ang II and Ang I displayed significantly lower cross-reactive values, averaging 0.06% (IC 50 of 200 pmol) and 0.005% (IC 50 of 2.7 nmol), respectively. Bradykinin and vasopressin did not show any significant cross-reactivity with the antibody. These data suggest that both the N-terminal and C-terminal sites of Ang-(1-7) were recognized by the monoclonal antibody.
Selected Abbreviations and Acronyms
ACE ϭ angiotensin-converting enzyme Ang I, II ϭ angiotensin I, II Ang-(1-5) ϭ angiotensin-(1-5) Ang-(1-7) ϭ angiotensin-(1-7) Ang-(2-7) ϭ angiotensin-(2-7) Ang-(3-7) ϭ angiotensin-(3-7) Ang-(1-7)-Ab ϭ monoclonal angiotensin-(1-7)
Neutralization of Endogenous Ang-(1-7)
Tail-cuff systolic blood pressure of SHR before initiation of treatment averaged 180Ϯ2 mm Hg. Group systolic and diastolic pressures averaged 112Ϯ3 mm Hg and 70Ϯ3 mm Hg (nϭ21), respectively, at day 9 after initiation of the combined therapy (lisinopril and losartan). In all experiments, injection of Ang II (0.1 mol/kg) did not elicit an increase in blood pressure, a finding that confirmed that the doses of losartan consumed by the rats as a part of the cotreatment protocol were sufficient to block the binding of Ang II to AT 1 receptors. Table 1 summarizes group baseline values of arterial pressure, heart rate, and plasma concentrations of Ang II and Ang-(1-7) in awake SHR treated with the combination of lisinopril and losartan. The combined treatment normalized the blood pressure of SHR, and this normalization was associated with high plasma concentrations of Ang-(1-7) but not Ang II. Fig 2 shows the changes in mean arterial pressure and heart rate produced by the infusion of either the Ang-(1-7)-Ab or IgG 1 in lisinopril-losartan-treated SHR. Administration of the monoclonal Ang-(1-7)-Ab resulted in a rapid and significant increase in mean arterial pressure that peaked within 1 minute after starting the infusion and amounted to an average rise of 19Ϯ3% above basal values. The elevation in mean arterial pressure produced by endogenous neutralization of Ang-(1-7) was primarily caused by a rise in diastolic blood pressure averaging 14Ϯ2 mm Hg, whereas systolic blood pressure rose by 9Ϯ2 mm Hg. The pressor response produced by endogenous neutralization of Ang-(1-7) lasted throughout the 15-minute infusion and was associated with a transient decrease in heart rate (Fig 2) . An infusion of comparable amounts of a purified IgG 1 had no effect on the arterial pressure and heart rate of chronically treated SHR (Fig 2) .
A separate group of SHR similarly treated with the combination of lisinopril and losartan was given [Sar ]Ang II in SHR rats not given PD123319 (vehicle-treated SHR) resulted in a significant increase in mean arterial pressure that was associated with nonsignificant bradycardia (Fig 3) . The increase in blood pressure elicited in these lisinopril-losartan-treated SHR was comparable in both magnitude (16Ϯ2% above baseline values) and duration with the changes obtained in the group of chronically treated SHR given the Ang-(1-7)-Ab (Fig 2) . As in the group of rats given the Ang-(1-7)-Ab, SHR given [Sar 1 -Thr 8 ]Ang II but not PD123319 showed a statistically significant greater rise in diastolic (ϩ14Ϯ2 mm Hg) than in systolic arterial pressure (ϩ7Ϯ1 mm Hg).
Administration of PD123319 had no effect on the baseline mean arterial pressure (78Ϯ2 mm Hg before and 78Ϯ2 mm Hg 1 hour after, PϾ.05) and heart rate (394Ϯ11 bpm before and 385Ϯ12 bpm 1 hour after, PϾ.05) of lisinopril-losartan-treated SHR. Subsequent infusion of [Sar 1 -Thr 8 ]Ang II in treated SHR administered PD123319 produced an increase in mean arterial pressure of a magnitude that did not differ from that recorded in treated SHR given the vehicle (Fig 3) . In SHR given PD123319 before administration of ]Ang II in PD123319-treated SHR were different than those obtained in SHR given the vehicle (Fig 3) . The changes in heart rate that accompanied the pressor response elicited by the infusion of [Sar ]Ang II were not statistically significant in PD123319-treated SHR (Fig 3) . To test for the possibility that the pressor response to [Sar Plasma levels of Ang-(1-7) and Ang II before and after infusions of either the Ang-(1-7)-Ab or IgG 1 are shown in Table 2 . The infusion of the Ang-(1-7)-Ab produced a twofold increase in plasma levels of Ang-(1-7), whereas plasma levels of Ang II did not change. In contrast, the infusion of IgG 1 did not alter plasma levels of either Ang-(1-7) or Ang II.
[Sar 1 -Thr 8 ]Ang II administration had no effect on plasma levels of either Ang-(1-7) or Ang II either in the absence or in the presence of PD123319 (Table 3) .
Discussion
These experiments evaluated the hypothesis that elevations in plasma Ang-(1-7) during combined therapy with lisinopril and losartan would contribute significantly to the normalization of arterial blood pressure in SHR. Our data showed that the combined therapy produced plasma concentrations of Ang-(1-7) higher than those documented by us 7, 8 and others 10 in SHR chronically treated with ACE inhibitors or losartan only. 8 In addition, we found that the acute infusion of a specific monoclonal antibody raised against Ang-(1-7) reversed the antihypertensive effect produced by lisinopril and losartan in awake SHR. These findings support the concept that Ang-(1-7) exerts biological actions distinct from Ang II. 1, 20 The antihypertensive mechanisms activated by Ang-(1-7) may result from the known effects of the heptapeptide on the production of vasodilator prostaglandins, 21 release of endothelial derived nitric oxide, 6 and potentiation of the hypotensive effects of bradykinin. 6 That the infusion of a competitive, mimics the effects of the Ang-(1-7)-Ab suggests that the antihypertensive actions of Ang-(1-7) are mediated by a non-AT 1 /AT 2 receptor subtype. Collectively, the results of the present studies add support to the concept that Ang-(1-7) counterbalances the pressor actions of Ang II. -(1-7) , its nonselective affinity for the AT 1 and AT 2 receptor subtypes impeded characterization of a specific role of Ang-(1-7) in the regulation of blood pressure. To circumvent this problem, we first evaluated the physiological actions of Ang-(1-7) with a purified anti-Ang-(1-7) polyclonal antibody. In these experiments, we showed that neutralization of endogenous brain Ang-(1-7) elicited a dose-dependent increase in the arterial pressure of transgenic hypertensive rats both in the absence and in the presence of lifetime treatment with lisinopril. 12 These data encouraged us to obtain a monoclonal antibody to Ang-(1-7) in order to enhance its specificity and provide a reliable and constant source of material in amounts greater than those resulting from the harvesting of polyclonal antibodies. The monoclonal antibody used in these experiments has a high affinity for Ang-(1-7), possesses little or no cross-reactivity with other angiotensin fragments (including Ang II), and does not bind to either bradykinin or vasopressin.
Infusion of the Ang-(1-7)-Ab in treated SHR elicited a prominent pressor response associated with transient bradycardia and increased levels of plasma Ang-(1-7). These effects were not duplicated by administration of IgG 1 . Although we did not perform a dose-response curve for the effect of increasing doses of the Ang-(1-7) antibody, we did ascertain that the amounts of the Ang-(1-7)-Ab used in the current experiments were sufficient to block the depressor response produced by 100 nmol of the peptide in the pithed rat. 13 From the data obtained in these experiments, we estimate that neutralization of Ang-(1-7) is associated with a reversal of at least one-third of the antihypertensive action produced by the combined medication. This interpretation is in keeping with the finding that a continuous infusion of Ang-(1-7) in SHR transiently reduced their elevated blood pressure by increasing the gain of the baroreceptor reflex and restoring vascular reactivity. 11, 22 Thus, the current experiments provide additional evidence for an important role of Ang-(1-7) in the chronic regulation of arterial pressure in hypertensive states.
Further evidence for the specificity of the response elicited by the monoclonal Ang-(1-7)-Ab is derived from the observation of a twofold rise in the plasma levels of Ang-(1-7). We interpret these findings as an indication that endogenous neutralization of Ang-(1-7) may retard peptide metabolism, because the bound peptide-antibody complex is prevented from binding to the catalytic site of aminopeptidases and ACE. 5, 6 Detection of high plasma levels of Ang-(1-7) after administration of the Ang-(1-7)-Ab may result from dissociation of the ligand-antibody complex during sample extraction, thus allowing a measure of both bound and unbound Ang-(1-7). Pace-Asciak et al 23, 24 reached a similar conclusion in studies of the endogenous trapping of 5,6-dihydroprostaglandin I 2 . In keeping with this interpretation, plasma levels of Ang II were not affected by endogenous neutralization of Ang-(1-7), whereas administration of [Sar 1 -Thr 8 ]Ang II caused no changes in the plasma Ang-(1-7) levels. This interpretation does not exclude, however, the possibility that sequestration of endogenous Ang-(1-7) by the circulating antibodies may prevent clearance of the peptide by the kidneys. 26, 27 In our studies, administration of PD123319 at doses reported to produce complete blockade of AT 2 receptors 28 had no effect on the blood pressure of lisinopril-and losartan-treated SHR. Thus, AT 2 receptors may not contribute to the normalization of blood pressure in SHR treated with the ACE inhibitor and the AT 1 receptor blocker. We tested for the possibility that the pressor response produced by [Sar 1 -Thr 8 ]Ang II was accounted for by the agonistic activity of this peptide antagonist. 29, 30 Infusion of [Sar 1 -Thr 8 ]Ang II had no effect on the arterial pressure or the heart rate of SHR treated with losartan for an equivalent time period. These data indicate that [Sar 1 -Thr 8 ]Ang II did not displace losartan from its AT 1 binding site. Moreover, in all of our studies injection of high doses of Ang II did not elicit a pressor response, a finding that suggested complete blockade of AT 1 receptors. Therefore, our data provide additional evidence for the existence of a functional subtype receptor mediating the endogenous action of Ang-(1-7) and possessing pharmacological characteristics distinct from AT 1 and AT 2 receptor subtypes. Other studies 31, 32 suggest the existence of a unique Ang-(1-7)-binding site that is not recognized by either losartan or PD123319. Tallant et al 31 described a high-affinity Ang-(1-7) binding site in bovine aortic endothelial cells that was displaced by [Sar 1 -Ile 8 ]Ang II but not losartan or PD123319. Nickenig et al 32 described a binding site for Ang-(1-7) in human skin fibroblasts that enhances DNA synthesis by a mechanism that is not prevented by pretreatment with either EXP-3174 or PD123319. 32 The potential role of angiotensin fragments, other than Ang II, in the long-term regulation of arterial pressure has just begun to be appreciated. 20, 33, 34 Studies by us 7, 8, 35 and others 10, 36 suggest that chronic inhibition of ACE does not suppress the formation of Ang II. The combination of an ACE inhibitor with an AT 1 receptor blocker may circumvent the limitations inherent in the mode of action of these classes of antihypertensive agents. 37 In humans, the combination of losartan with either captopril 38 or enalapril 39 has an additive effect on lowering blood pressure. The additive effect suggests that Ang II production persists during chronic ACE inhibition. We now suggest that the additional antihypertensive effect achieved by the combined therapy may be related, at least in part, to increased production of Ang-(1-7) and reduced Ang-(1-7) metabolism. This interpretation is consistent with the finding of a 357% rise in plasma levels of Ang-(1-7) when compared with the values found in lisinopril-treated SHR. 7 In addition, the increases in plasma Ang-(1-7) levels during the combined treatment were accompanied with blood pressure levels that were significantly below those determined in SHR treated with lisinopril 7 or transgenic hypertensive rats given losartan alone for a comparable time period. Thus, these data suggest that Ang-(1-7) contributes to mediating the antihypertensive effects obtained with the combined therapy.
The observation that [Sar 1 -Thr 8 ]Ang II reversed the antihypertensive effects of the combined treatment is a new finding. As indicated above, we confirmed that the combined treatment was associated with inhibition of the pressor response to systemic injections of Ang II and that concomitant blockade of AT 2 receptors had no additional effect on baseline blood pressure or plasma concentrations of Ang II. The new findings support the existence of a [Sar 1 -Thr 8 ]Ang II-sensitive site contributing directly to the mechanism by which blockade of the renin-angiotensin system translates into the reversal of arterial hypertension in SHR.
In summary, our study provides physiological evidence for a role of endogenous Ang-(1-7) in contributing to the antihypertensive action of combined blockade of ACE and AT 1 receptors in SHR. The mechanism of action may involve a receptor site recognized by [Sar ]Ang II but not by AT 1 -or AT 2 -selective antagonists. The question of whether the acute effects of endogenous neutralization of Ang-(1-7) play a long-term role in the maintenance of the controlled blood pressure needs further investigation. Nevertheless, the present studies extend the observation that chronic infusions of Ang-(1-7) mimic the effects of ACE inhibition in SHR, 11 whereas neutralization of endogenous brain Ang-(1-7) reverses the antihypertensive actions of lifetime treatment with lisinopril in transgenic hypertensive rats. 
